Quantcast
Home > Quotes > SESN
SESN

Sesen Bio, Inc. Common Stock (SESN) Quote & Summary Data

$1.6
*  
0.09
5.33%
Get SESN Alerts
*Delayed - data as of Nov. 14, 2018  -  Find a broker to begin trading SESN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SESN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.74 / $ 1.5627
Share Volume
1,147,094
50 Day Avg. Daily Volume
989,877
Previous Close
$ 1.69
52 Week High / Low
$ 3.50 / $ 0.63
Market Cap
123,217,598
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,147,094
50 Day Avg. Daily Volume:
989,877

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.67

Trading Range

The current last sale of $1.60 is 153.97% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.74 $ 3.50
 Low: $ 1.5627 $ 0.63

Company Description (as filed with the SEC)

We are a biologics oncology company focused primarily on designing, engineering and developing targeted protein therapeutics, or TPTs. Our TPTs are single protein therapeutics composed of targeting moieties genetically fused via a peptide linker domain to cytotoxic protein payloads that are produced through our proprietary recombinant one-step manufacturing process. We target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. We have designed our TPTs to overcome the fundamental efficacy and safety challenges inherent in existing antibody drug conjugates, or ADCs, where a payload is chemically attached to a targeting antibody. Our most advanced product candidate is ViciniumTM, which is a locally-administered TPT.  ... More ...  


Risk Grade

Where does SESN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.73
Open Date:
Nov. 14, 2018
Close Price:
$ 1.60
Close Date:
Nov. 14, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x